The North America clinical trial imaging market size was valued at USD 428 million in 2025 and is projected to grow from USD 466.09 million in 2026 to USD 921.92 million by 2034 at a CAGR of 8.9% during the forecast period 2026-2034.
However, applying this knowledge in clinical settings has not kept pace with the rate of discovery. Developing new drugs involves several steps, one of which is conducting clinical trials. A clinical trial imaging (CTI) study is a research study in which participants participate voluntarily. Each study examines a unique scientific question concerning the usefulness of imaging technologies in detecting illness, diagnosing it, guiding treatment, or monitoring its progress. Imaging techniques for clinical trials can be broken down into the following categories: In general, screening imaging clinical trials ask questions to help researchers determine which type of imaging test will detect disease early, possibly before symptoms appear.
Clinical trials involving diagnostic imaging investigate which types of imaging tests are most likely to effectively detect disease when only a suspicion of disease exists, which types of imaging tests can assist in monitoring a known condition, and which types of imaging tests can monitor the effectiveness of a therapy to determine whether or not it is working. Image-guided interventional clinical trials are designed to evaluate the efficacy of interventions that are guided by imaging.
Imaging techniques are becoming increasingly important in the provision of evidence for decision making in oncological clinical trials. Imaging is still used to define key study end points, even though conventional morphological imaging techniques and standardised response criteria that are based on tumour size measurements have been implemented.
Download a Free Sample To learn more about this report,
A physical or mental health condition that lasts more than one year and causes functional restrictions or requires ongoing monitoring or treatment is considered to be a chronic condition. Chronic diseases are some of the most common and expensive health conditions that affect people in the United States. Almost half of all Americans, or about 133 million, have at least one chronic disease and the number has been rising. Chronic diseases, like cancer, diabetes, high blood pressure, stroke, heart disease, respiratory diseases, arthritis, obesity, and oral diseases, can cause hospitalisation, long-term disability, a lower quality of life, and even death. In fact, chronic conditions are the leading cause of death and disability in the United States. This problem will drive the demand of CTI.
R&D spending and its outcomes Over the last two decades, both R&D spending and the introduction of new drugs have increased. In 2019, the pharmaceutical industry in U.S. spent $83 billion on research and development. When adjusted for inflation, that sum is roughly ten times what the industry spent each year in the 1980s. The number of newly developed medicines that were given the go-ahead to be sold reached a record high of 59 in 2018, marking a 60 percent increase compared to the previous decade in terms of the number of products that were given the green light. This increment would propel the growth in this market.
In addition, in the coming years, an increase in the expansion of a variety of pharmaceutical and biotechnology industries, particularly in economies that are still in the process of developing, would therefore further provide possible future opportunities for the growth of the North America clinical trial imaging market.
The trial is very expensive and the organizations which conduct those trials bear a huge cost because of its high maintenance cost. This factor is expected to impede the growth of this market. In the United States, the costs of phase 1, 2, and 3 clinical trials range from US$1.4-6.6, 7.0-19.6, and 11.5-52.9 million, respectively.
The total cost of a clinical trial is determined by a number of factors, the most important of which are:
(1) the number of participants and
(2) the complexity of the clinical trial protocol.
The number of clinical trial participants is highly related to the study phase.
Services hold a prominent position in the North American clinical trial imaging market because imaging studies require specialized planning, standardized acquisition, independent interpretation, and regulatory-compliant data handling. Pharmaceutical and biotechnology companies frequently rely on external imaging specialists to maintain consistency across multiple research locations. Demand is also supported by the increasing complexity of oncology, neurology, cardiovascular, and metabolic disease trials. Centralized image review, quality assurance, reader management, and data analysis help sponsors reduce variability, improve endpoint reliability, and accelerate evidence generation throughout clinical development.
Software supports the collection, transfer, storage, visualization, and analysis of medical images generated during clinical trials. Modern platforms help research teams manage large imaging datasets while enabling secure collaboration among investigators, sponsors, imaging laboratories, and clinical research organizations. Adoption is increasing as decentralized and multicenter studies require faster data exchange and consistent image evaluation. Artificial intelligence, cloud-based deployment, workflow automation, and advanced visualization tools are also improving software capabilities. These solutions help reduce manual work, identify image-quality problems, and maintain traceable records for regulatory review.
Request Customizationto receive a tailored report.
Operational imaging services are experiencing strong demand because they coordinate imaging activities across research sites and help ensure that every scan follows the approved clinical protocol. Providers manage site qualification, equipment validation, imaging manual development, technologist training, scan scheduling, image transfer, and quality control. These activities are especially important for large multicenter trials where differences in scanners and operating procedures can affect study results. Increasing trial complexity, broader use of imaging biomarkers, and the expansion of geographically distributed research networks are supporting demand for structured operational imaging services.
Clinical trial design and consultation services help sponsors select appropriate imaging endpoints, modalities, schedules, and assessment criteria. Reading and analytical services provide centralized interpretation and quantitative measurement of trial images. CT, MRI, X-ray, ultrasound, OCT, and other imaging approaches are selected according to the disease, tissue, and endpoint being evaluated. System and technology support maintains platform performance and resolves technical issues, while project and data management services organize timelines, submissions, image records, and communication. Together, these services improve consistency and protect the reliability of clinical evidence.
Oncology represents a major application area because diagnostic imaging is essential for identifying tumors, measuring treatment response, monitoring disease progression, and supporting patient selection. CT, MRI, nuclear imaging, ultrasound, and emerging quantitative techniques are frequently incorporated into cancer trials as primary or secondary endpoints. Demand is reinforced by the large number of studies involving targeted therapies, immunotherapies, combination treatments, and precision medicine. Standardized image review helps investigators compare results across sites, reduce subjective interpretation, and determine whether experimental therapies produce meaningful changes in tumor burden or biological activity.
In NASH studies, imaging enables noninvasive assessment of liver fat, inflammation, and fibrosis, while CKD and diabetes trials use it to examine organ structure and disease complications. Cardiovascular studies rely on imaging to evaluate vascular function, cardiac anatomy, and treatment effects. Neurology trials use brain and spinal imaging to monitor structural or functional changes. Endocrinology, dermatology, and hematology research also apply specialized imaging methods to document disease activity. Other applications include musculoskeletal, respiratory, ophthalmic, and rare-disease studies requiring objective and repeatable clinical endpoints.
Contract research organizations are showing strong adoption of clinical trial imaging as sponsors increasingly outsource complex study activities to experienced external partners. CROs coordinate imaging vendors, research sites, readers, technology platforms, and data-management teams across the trial lifecycle. Their involvement helps pharmaceutical and biotechnology companies control operational workloads while maintaining standardized procedures and regulatory documentation. Demand is further supported by multicenter studies, global development programs, and trials involving advanced imaging biomarkers. Integrated imaging capabilities allow CROs to improve site compliance, accelerate issue resolution, and deliver more consistent datasets.
Biotechnology and pharmaceutical companies use clinical trial imaging to evaluate drug safety, biological activity, and therapeutic effectiveness across development phases. Medical device manufacturers depend on imaging to confirm device placement, monitor performance, and generate evidence for regulatory submissions. Academic and government research institutes apply imaging in investigator-led studies, public health research, and the development of new diagnostic methods. Other end users include hospitals, independent imaging centers, specialized laboratories, and nonprofit research organizations. These groups contribute clinical expertise, patient access, equipment infrastructure, and disease-specific knowledge to imaging-based studies.
Direct sales remain an important distribution route because clinical trial imaging solutions are often customized according to the sponsor’s protocol, therapeutic area, study size, and technology requirements. Direct engagement allows providers to understand trial objectives, recommend suitable services, and configure software or analytical workflows around specific endpoints. It also supports detailed contract discussions, implementation planning, technical integration, and ongoing account management. Sponsors often prefer this route for complex or long-duration studies because it provides clearer communication, faster troubleshooting, and closer coordination between imaging specialists and internal clinical development teams.
Tender sales are commonly used by government institutions, academic research organizations, hospitals, and large research networks that follow formal procurement procedures. This channel promotes structured vendor comparison based on technical capability, service coverage, security, compliance, implementation schedules, and overall commercial terms. Tender-based procurement can be particularly relevant for publicly funded studies, institutional imaging programs, and multi-year research projects. Vendors competing through this route must provide detailed documentation and demonstrate operational capacity. Transparent selection processes also help purchasers identify solutions that meet predefined clinical, technological, and administrative requirements.
Speak to an Analystto discuss market opportunities.
The North America clinical trial imaging market report covers the United States, Canada, and Mexico.
Because of its large number of companies and research and development capabilities, the United States dominates the clinical trial imaging market. Furthermore, the emergence of major key players and an increase in government healthcare initiatives will fuel the growth of the North America clinical trial imaging market during the forecast period.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Ambulance Services Market Size, Share, Growth, Analysis, 2034
Europe Clinical Trial Imaging Market Analysis, Trends, Forecast Up to 2034
Asia Pacific Clinical Trial Imaging Market Size, Share and Forecast to 2034
India Pharmaceutical Stability and Storage Services Market Size, Share & Trends | Industry Report, 2034
Healthcare Regulatory Affairs Outsourcing Market Size, Share, 2034
Facial Fat Transfer Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com